Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLRA trial of rituximab versus placebo in rheumatoid arthritis-associated interstitial lung disease
2025-524872-51-00Phase 4Authorised
- Sponsor
- Region Västra Götaland
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Interstitial Lung Disease Rheumatoid Arthritis Related (RA-ILD) comparing Rituximab with Placebo (2 arms). Primary endpoint: Mean absolute change in percent predicted forced vital capacity. Planned start Feb 2026; status: authorised.
02
Drugs
rituximab
03
Conditions
Interstitial Lung Disease Rheumatoid Arthritis Related (RA-ILD)
Beyond the preview
Go deeper on 2025-524872-51-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524872-51-00.